SEC Form 4 · accession 0001209191-17-031515
CRESCENT BIOPHARMA, INC. · CBIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John L. Magnani
Officer — SVP of Research, CSO · Director
Period of report
May 10, 2017
Accepted (ET)
May 11, 2017 · 4:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001253689
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | May 10, 2017 | M | 8,928 | $1.12 | A | 99,302 | D | |
| Common StockF1 | holding | — | — | — | 4,845 | I | By GlycoTech Corporation |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F2 | $1.12 | May 10, 2017 | M | 8,928 | D | — | Jan 4, 2021 | Common Stock | 8,928 | 213,967 | D |
Explanation of responses
- F1These shares are held by GlycoTech Corporation, of which the reporting person is the sole stockholder.
- F2One-fourth of the shares underlying this option vested on January 4, 2012, with the remainder vesting in 36 equal monthly installments thereafter.